Sara Tedeschi, MD, MPH: Avalo Therapeutics: Consultant (Ongoing); Merck: Consultant (Ongoing); Novartis: Consultant (Terminated, December 19, 2022)
Update in CPPD disease classification criteria, long-term outcomes, and treatments
Learning Objectives:
Recognize key elements for classifying a patient as having CPPD disease for research studies
Recall long-term outcomes associated with CPPD disease
Identify and compare the efficacy of a short course of prednisone versus colchicine for treating a flare of acute calcium pyrophosphate crystal arthritis (pseudogout)
